Valuation: Realcan Pharmaceutical Group Co., Ltd.

Market Cap 4B 601M 538M 495M 448M 838M 57.04B 854M 5.9B 2.37B 30.01B 2.25B 2.21B 94.63B P/E 2024
217x
P/E 2025 322x
Enterprise Value 4.86B 730M 654M 601M 545M 1.02B 69.32B 1.04B 7.17B 2.88B 36.46B 2.74B 2.68B 115B EV / Sales 2024
0.76x
EV / Sales 2025 0.77x
Free-Float
69.3%
Yield 2024
0.37%
Yield 2025 0.06%
10-26 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2026 CI
09-20 Realcan Pharmaceutical Group Co., Ltd.(XSEC:002589) added to S&P Global BMI Index CI
08-20 Realcan Pharmaceutical Group Co., Ltd. Approves the Election of Lv Kaiqiang and Wu Bin as Independent Director CI
08-20 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
05-19 Realcan Pharmaceutical Group Co., Ltd. Approves Cash Dividend for 2025 for A shares, Payable on 30 June 2026 CI
04-24 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-22 Realcan Pharmaceutical Group Co., Ltd. announces Annual dividend, payable on June 30, 2026 CI
04-22 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-07 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
11-06 Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on November 11, 2024, has closed with 34,638,659 shares, representing 2.31% for CNY 101.48 million. CI
29/10/25 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
13/10/25 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
25/08/25 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
1 day-1.09%
1 week-6.21%
Current month-16.82%
1 month-16.82%
3 months+0.37%
6 months-14.47%
Current year-15.53%
1 week 2.69
Extreme 2.69
2.93
1 month 2.69
Extreme 2.69
3.38
Current year 2.38
Extreme 2.38
4.11
1 year 2.38
Extreme 2.38
4.69
3 years 2.05
Extreme 2.05
4.69
5 years 2.05
Extreme 2.05
6.73
10 years 2.05
Extreme 2.05
18.26
Manager TitleAgeSince
Director of Finance/CFO 56 25/04/2021
President 61 25/05/2023
Corporate Officer/Principal 40 29/10/2019
Director TitleAgeSince
Chairman 61 20/11/2009
Director/Board Member 43 20/11/2009
Director/Board Member 71 18/05/2023
Date Insider Type Main position Quantity % Market Cap. Importance
12/05/23 Sell

Founder

15,000,000 1.2902%
30/03/23 Sell

Founder

13,040,000 1.1260%
30/03/23 Sell

Chairman

2,000,000 0.1727%
Change 5-day change 1-year change 3-year change Capi.($)
-1.09%-6.21%-4.90%-24.23% 607M
+3.19%+11.31%+67.86%+150.58% 1,224B
-0.73%+3.56%+44.51%+85.81% 662B
+1.41%+3.24%+29.22%+107.83% 514B
+0.42%+3.20%+54.15%+67.18% 388B
+2.18%+2.93%+73.30%+45.62% 361B
+1.12%+4.52%+35.30%+58.08% 302B
+6.96%+8.86%+11.27%+36.62% 271B
+1.15%+6.09%+59.59%+77.06% 249B
+3.06%+9.38%+44.11%+119.47% 205B
Average +1.45%+4.39%+41.44%+72.40% 417.75B
Weighted average by Cap. +1.17%+6.35%+50.90%+98.21%

Financials

2024 2025
Net sales 7.97B 1.2B 1.07B 986M 893M 1.67B 114B 1.7B 11.76B 4.72B 59.78B 4.49B 4.4B 189B 7.3B 1.1B 982M 903M 818M 1.53B 104B 1.56B 10.77B 4.32B 54.75B 4.11B 4.03B 173B
Net income 20.62M 3.1M 2.77M 2.55M 2.31M 4.32M 294M 4.4M 30.44M 12.22M 155M 11.63M 11.38M 488M 16.07M 2.41M 2.16M 1.99M 1.8M 3.37M 229M 3.43M 23.72M 9.52M 121M 9.06M 8.87M 380M
Net Debt 1.6B 240M 215M 197M 179M 334M 22.76B 341M 2.35B 945M 11.97B 900M 880M 37.76B 860M 129M 116M 106M 96.48M 180M 12.27B 184M 1.27B 510M 6.46B 485M 475M 20.36B
Projected Income Statement - Annual - Realcan Pharmaceutical Group Co., Ltd.
Logo Realcan Pharmaceutical Group Co., Ltd.
Realcan Pharmaceutical Group Co Ltd, formerly Realcan Pharmaceutical Co Ltd, is a China-based company mainly engaged in the provision of comprehensive medical service. The Company operates five businesses. The drug and device distribution business is mainly responsible for drug and device distribution services and comprehensive medical services. The in vitro diagnostic business covers all fields such as laboratory biochemistry, immunity, and clinical examination. The digital health business provides one-stop health management solutions. The pharmaceutical logistics business provides pharmaceutical and medical device logistics services. The traditional Chinese medicine business is engaged in the research, development and production of traditional Chinese medicine pieces, granules, new traditional Chinese medicines, liquefied traditional Chinese medicine products, and health foods. The Company mainly operates in the domestic market, with Shandong as its main market.
Employees
2,407
Date Price Change Volume
30/10/26 CN¥2.720 -1.09% 58,932,570
29/10/26 CN¥2.750 -2.14% 35,192,564
28/10/26 CN¥2.810 +0.72% 36,907,252
27/10/26 CN¥2.790 -4.12% 50,043,591
26/10/26 CN¥2.910 +0.34% 44,423,600
  1. Stock Market
  2. Stocks
  3. 002589 Stock